Compare DexCom, Inc. (DXCM) vs iShares 3 7 Year Treasury Bond ETF (IEI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs iShares 3 7 Year Treasury Bond ETF — how do they compare? DexCom, Inc. trades at $84.03 (market cap $31.86B), while iShares 3 7 Year Treasury Bond ETF trades at $113.5 (market cap $16.72B). The key difference: DexCom, Inc. is the larger of the two by market cap, and DexCom, Inc. is trading nearer its 52-week high, iShares 3 7 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and iShares 3 7 Year Treasury Bond ETF for 43 Days on average.
| DXCM | IEI | |
|---|---|---|
Market Cap | $31.86B | $16.72B |
Volume | 3,607,070 | 3,963,319 |
Sector | Health | Fixed Income |
52-Week High | $92.34 | $120.72 |
52-Week Low | $54.84 | $113.17 |
Typical Hold Time | 62 Days | 43 Days |
Enterprise Value | $31.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.03, down 0.32% on the day, with strong fundamental performance including three consecutive quarterly EPS beats and robust 20.12% net income margin. The stock shows bearish technical signals with price near pivot point support at $84, while analyst consensus remains overwhelmingly positive with 81% buy ratings and $95.07 price target representing 13% upside potential. Recent news highlights expansion opportunities in Type 2 diabetes care and executive promotions.
DXCM presents a compelling growth story with expanding profit margins and consistent earnings outperformance, though technical weakness and premium valuation create near-term headwinds. The company's leadership in continuous glucose monitoring and Type 2 diabetes market expansion provide long-term catalysts, while competition and reimbursement risks require monitoring.
IEI trades at $113.465 with minimal daily movement (+0.07%), showing technical bearish signals from moving averages while oscillators remain neutral. The stock faces resistance at $114 with support at $113. Recent dividend payments of $0.37-0.38 demonstrate consistent shareholder returns, though key financial ratios remain unavailable for fundamental assessment.
The bearish technical outlook and lack of fundamental data create uncertainty. Bond market volatility and rising Treasury yields present macroeconomic headwinds. Investment potential depends on forthcoming financial disclosures and the company's ability to navigate current interest rate environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About iShares 3 7 Year Treasury Bond ETF
IEI tracks the ICE U.S. Treasury 3-7 Year Bond Index, offering exposure to intermediate-term government debt. It serves as a conservative middle ground in the Treasury yield curve, providing higher yields than short-term bills with less volatility than long-term bonds.
Read more on IEI →
